Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 2/20 | 0.58 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | IL1RN | P18510 | 1/20 | 0.50 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | MLKL | Q8NB16 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 2/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.43 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6513331 | 0.88 | GRIA4 (0.54) | KEAP1MLKLKDM1APGRGRIA4 | |
| SCHEMBL1677246 | 0.83 | KDM1A (0.64) | CA2CA9KDM1AGRIA4 | |
| SCHEMBL13566019 | 0.83 | CA1 (0.50) | CA1CA2CA12CA9KMT2A | |
| SCHEMBL18638754 | 0.83 | KEAP1 (0.54) | KEAP1CA1CA2IL1RNERAP1 | |
| SCHEMBL18722578 | 0.83 | KEAP1 (0.54) | KEAP1CA1CA2IL1RNERAP1 | |
| SCHEMBL10116458 | 0.82 | GRIA4 (0.60) | KMT2AMEN1PKMALDH1A1TDP1 | |
| SCHEMBL10191865 | 0.80 | CA1 (0.57) | CA1CA2CA12CA9KMT2A | |
| SCHEMBL14191076 | 0.79 | KEAP1 (0.50) | KEAP1CA1CA2IL1RNERAP1 | |
| SCHEMBL2562502 | 0.79 | GRIA4 (0.65) | CA1CA2CA12CA9KMT2A | |
| SCHEMBL5937275 | 0.78 | CA1 (0.55) | CA1CA2PKMPGRGRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112574255-B | Organic arsine-based CDK inhibitor and preparation method and application thereof | 中国科学院上海有机化学研究所 | 2024-05-10 | — | — | CN | disclosed |
| US-11814388-B1 | Substituted pyrrolo[2,3-d]pyrimidines and pyrazolo[3,4-d]pyrimidines as inhibitors for multi-resistant cancers | FERRIS STATE UNIVERSITY (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814388-B1 | Substituted pyrrolo[2,3-d]pyrimidines and pyrazolo[3,4-d]pyrimidines as inhibitors for multi-resistant cancers | FERRIS STATE UNIVERSITY (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-08-03 | — | — | US | disclosed |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11649223-B2 | Amino compounds for treatment of immune and inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11649229-B2 | Amide compounds for treatment of immune and inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| CN-110642796-B | Quinazoline derivative and application thereof | 烟台药物研究所 | 2023-03-17 | — | — | CN | disclosed |
| CN-101535276-A | 2, 4-diaminopyrimidine fused bicyclic derivatives as ALK and c-MET inhibitors | CEPHALON INC (US) | 2009-09-16 | — | — | CN | disclosed |
| US-20090221643-A1 | 4-PHENYL-3-(2-PROPYLSULFONYLAMINO) TETRAHYDROFURAN DERIVATIVES WHICH POTENTIATE GLUTAMATE RECEPTORS AND ARE USEFUL IN THE TREATMENT OF SCHIZOPHRENIA | GLAXO GROUP LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-07-16 | — | — | US | disclosed |
| EP-1981865-A1 | 4-PHENYL-3-(2-PROPYLSULFONYLAMINO) TETRAHYDROFURAN DERIVATIVES WHICH POTENTIATE GLUTAMATE RECEPTORS AND ARE USEFUL IN THE TREATMENT OF SCHIZOPHRENIA | GLAXO GROUP LIMITED (GB) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007090840-A1 | 4-PHENYL-3-(2-PROPYLSULFONYLAMINO) TETRAHYDROFURAN DERIVATIVES WHICH POTENTIATE GLUTAMATE RECEPTORS AND ARE USEFUL IN THE TREATMENT OF SCHIZOPHRENIA | GLAXO GROUP LIMITED (GB) | 2007-08-16 | — | — | WO | disclosed |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | INCYTE CORPORATION | 2007-06-14 | — | — | US | disclosed |
| EP-1146037-B1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE AMINO ALCOHOLS | NIPPON SODA CO (JP) | 2006-06-21 | — | — | EP | disclosed |
| US-6410749-B1 | REACTING A CARBONYL COMPOUND WITH ORGANOMETALLIC COMPOUND | NIPPON SODA CO., LTD. (JP) | 2002-06-25 | — | — | US | disclosed |
| EP-1146037-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE AMINO ALCOHOLS | NIPPON SODA CO., LTD. (JP) | 2001-10-17 | — | — | EP | disclosed |
| US-4623391-A | COMPOUNDS HAVING ELECTRON-WITH DRAWING GROUPS WITHIN FIVE ATOMS OF A SULFANAMIDE | THE STANDARD REGISTER COMPANY (US) | 1986-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | BCL6, SOX18, BCL3 | KEAP1 463/4885CA1 3919/4885CA2 4239/4885 |
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | CFD, TFPI, CFH | KEAP1 1574/4885CA1 4118/4885CA2 3553/4885 |
| US-11649229-B2 | Amide compounds for treatment of immune and inflammatory disorders | CFD, TFPI, CFH | KEAP1 1260/4885CA1 4041/4885CA2 3411/4885 |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | KEAP1 1248/4885CA1 4847/4885CA2 3829/4885 |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | KEAP1 1248/4885CA1 4847/4885CA2 3829/4885 |
| US-20090221643-A1 | 4-PHENYL-3-(2-PROPYLSULFONYLAMINO) TETRAHYDROFURAN DERIVATIVES WHICH POTENTIATE GLUTAMATE RECEPTORS AND ARE USEFUL IN THE TREATMENT OF SCHIZOPHRENIA | GRIN2C, GRIN1, OXER1 | KEAP1 1939/4885CA1 863/4885CA2 1356/4885 |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | JAK1, JAK3, MAP3K4 | KEAP1 1136/4885CA1 4881/4885CA2 4789/4885 |
| US-11649223-B2 | Amino compounds for treatment of immune and inflammatory disorders | CFD, TFPI, CFH | KEAP1 1087/4885CA1 4556/4885CA2 3883/4885 |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | KEAP1 2090/4885CA1 4883/4885CA2 4482/4885 |
| US-11814388-B1 | Substituted pyrrolo[2,3-d]pyrimidines and pyrazolo[3,4-d]pyrimidines as inhibitors for multi-resistant cancers | AURKA, AURKC, AURKB | KEAP1 3604/4885CA1 2753/4885CA2 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.